JP2024059648A5 - - Google Patents

Download PDF

Info

Publication number
JP2024059648A5
JP2024059648A5 JP2024014560A JP2024014560A JP2024059648A5 JP 2024059648 A5 JP2024059648 A5 JP 2024059648A5 JP 2024014560 A JP2024014560 A JP 2024014560A JP 2024014560 A JP2024014560 A JP 2024014560A JP 2024059648 A5 JP2024059648 A5 JP 2024059648A5
Authority
JP
Japan
Prior art keywords
drawings
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024014560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024059648A (ja
JP7760626B2 (ja
Filing date
Publication date
Priority claimed from JP2021573616A external-priority patent/JP7512310B2/ja
Application filed filed Critical
Publication of JP2024059648A publication Critical patent/JP2024059648A/ja
Publication of JP2024059648A5 publication Critical patent/JP2024059648A5/ja
Application granted granted Critical
Publication of JP7760626B2 publication Critical patent/JP7760626B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024014560A 2019-06-11 2024-02-02 治療に使用するための抗ソルチリン抗体 Active JP7760626B2 (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962860207P 2019-06-11 2019-06-11
US62/860,207 2019-06-11
US201962868850P 2019-06-28 2019-06-28
US62/868,850 2019-06-28
US201962874475P 2019-07-15 2019-07-15
US62/874,475 2019-07-15
US201962947503P 2019-12-12 2019-12-12
US62/947,503 2019-12-12
US202062961591P 2020-01-15 2020-01-15
US62/961,591 2020-01-15
JP2021573616A JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体
PCT/US2020/037054 WO2020252066A1 (en) 2019-06-11 2020-06-10 Anti-sortilin antibodies for use in therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021573616A Division JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体

Publications (3)

Publication Number Publication Date
JP2024059648A JP2024059648A (ja) 2024-05-01
JP2024059648A5 true JP2024059648A5 (enExample) 2025-02-28
JP7760626B2 JP7760626B2 (ja) 2025-10-27

Family

ID=71948712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573616A Active JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体
JP2024014560A Active JP7760626B2 (ja) 2019-06-11 2024-02-02 治療に使用するための抗ソルチリン抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021573616A Active JP7512310B2 (ja) 2019-06-11 2020-06-10 治療に使用するための抗ソルチリン抗体

Country Status (12)

Country Link
US (2) US20200392229A1 (enExample)
EP (1) EP3983441A1 (enExample)
JP (2) JP7512310B2 (enExample)
KR (1) KR20220031616A (enExample)
CN (1) CN114423450B (enExample)
AU (1) AU2020291527A1 (enExample)
BR (1) BR112021025077A2 (enExample)
CA (1) CA3140023A1 (enExample)
IL (1) IL288728A (enExample)
MX (1) MX2021015212A (enExample)
TW (1) TWI877170B (enExample)
WO (1) WO2020252066A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
JP2023553399A (ja) * 2020-12-02 2023-12-21 アレクトル エルエルシー 抗ソルチリン抗体の使用法
EP4351728A4 (en) * 2021-06-08 2025-08-27 Alector Llc METHODS OF USING ANTI-SORTILIN ANTIBODIES
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
PT2748201T (pt) 2011-08-23 2018-02-08 Roche Glycart Ag Moléculas de ligação ao antigénio biespecíficas que ativam as células t
LT3280441T (lt) * 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
CN110831975A (zh) 2017-04-21 2020-02-21 因普利西特生物科学私人有限公司 用于治疗神经退行性疾病的cd14拮抗剂抗体
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
PE20210186A1 (es) * 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso

Similar Documents

Publication Publication Date Title
JP2022191211A5 (enExample)
JP2020127044A5 (enExample)
JP2025138632A5 (enExample)
JP2024059739A5 (enExample)
JP2025120176A5 (enExample)
JP2022068302A5 (enExample)
JP2020127428A5 (enExample)
JP2024129139A5 (enExample)
JP2024059648A5 (enExample)
JP2023022224A5 (enExample)
JP2025160313A5 (enExample)
JP2024016014A5 (enExample)
JP2024112817A5 (enExample)
JP2023085551A5 (enExample)
JP2022060295A5 (enExample)
JP2023100643A5 (enExample)
JPWO2019148052A5 (enExample)
JP2024099716A5 (enExample)
JP2023011759A5 (enExample)
JP2024170456A5 (enExample)
JP2024063214A5 (enExample)
JP2025066722A5 (enExample)
JP2022172276A5 (enExample)
JP2023175831A5 (enExample)
JP2023153118A5 (enExample)